Overview on human breast cancer with focus on prognostic and predictive factors with special attention on the tumour suppressor gene p53

Acta Oncologica

Volumn 35, Issue SUPPL. 5, 1996, Pages 96-102

  Norberg, T ^a   Jansson, T ^a   Sjogren S ^a   Martensson C ^a   Andreasson I ^a   Fjallskog M L ^a   Lindman, H ^a   Nordgren, H ^a   Lindgren, A ^b   Holmberg, L ^a   Bergh, J ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b FALUN HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CATHEPSIN D; PLASMINOGEN ACTIVATOR;

ADULT; AGED; BREAST CANCER; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; ONCOGENE; PRIORITY JOURNAL; PROGNOSIS; TUMOR SUPPRESSOR GENE;

APOPTOSIS; BREAST NEOPLASMS; GENES, P53; HUMANS; LYMPHATIC METASTASIS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 0030483426     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.3109/02841869609083980     Document Type: Review

References (60)

1. Allegra J, Lippman M, Thompson E, et al. Estrogen receptor status: An important variable in predicting response to endocrine therapy in metastatic breast cancer. Eur J Cancer 1980; 16: 323-31.2.
2. Campbell FC, Elston CW, Blarney RW, et al. Quantitative oestradiol receptor values in primary breast cancer and response of metastases to endocrine therapy. Lancet 1981; 2: 1317-9.
3. Henderson IC. Endocrine therapy in metastatic breast cancer. In: Harris JR, Hellman S, Henderson IC, Kinne DW (eds), Breast diseases, pp 398-428. Philadelphia, JB Lippincott, 1987.
4. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 1992; 339: 1-15, 71-85.
5. Rutqvist LE, Hatschek T, Rydén S, et al. Randomized trial of 2 versus 5 years of adjuvant tamoxifen in postmenopausal early-stage breast cancer. Submitted The Lancet.
6. Klijn JGM, Berns EMJJ, Foekens JA. Prognostic factors and response to therapy in breast cancer. Cancer Surveys 1993; 18: 165-98.
7. Stål O, Skoog L, Rutqvist LE, et al. S-phase fraction and survival benefit from adjuvant chemotherapy or radiotherapy. Br J Cancer 1994; 70: 1258-62.
8. Fernö M, Baldetorp B, Borg Å, et al. Cathepsin D, both a prognostic factor and a predictive factor for the effect of adjuvant tamoxifen in breast cancer. Eur J Cancer 1994; 30A: 2042-8.
9. Damstrup L, Andersen J, Kufe DW, Hayes DF, Skovgaard Poulsen H. Immunocytochemical determination of the estrogen-regulated proteins Mr 24 000 Mr 52 000 and DF3 breast cancer associated antigen: clinical value in advanced breast cancer and correlation with estrogen receptor. Annals Oncol 1992; 3: 71-7.
10. Foekens JA, Look MP, Peters HA, van Putten WLJ, Portengen H, Klijn JGM. Urokinase-type plasminogen activator and its inhibitor PAI-1: Predictors of poor response to tamoxifen therapy in recurrent breast cancer. J Natl Cancer Inst 1995; 87: 751-6.
11. Muss HB, Thor AD, Berry DA, et al. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 1994; 330: 1260-6.
12. Stål O, Sullivan S, Wingren S, et al. c-erbB-2 expression and benefit from adjuvant chemotherapy and radiotherapy of breast cancer. Eur J Cancer 1995; 31A: 2185-90.
13. Allred DC, Clark GM, Tandon AK, et al. HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma. J Clin Oncol 1992; 10: 599-605.
14. Gusterson BA, Belber RD, Goldhirsch A, et al. Prognostic importance of c-erbB-2 expression in breast cancer. J Clin Oncol 1992; 10: 1049-56.
15. Bissonnette RP, Shi Y Mahboubi A, Glynn JM, Green DR. C-myc and apoptosis. In: Tomei DL, Cope FO (eds). Apoptosis II. The molecular basis of apoptosis in disease. New York: Gold Spring Harbor Laboratory Press 1994; 327-56.
16. Cole SPC, Bhardwaj G, Gerlach JH, et al. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 1992; 258: 1650-4.
17. Chin KV, Pastan I, Gottesman MM. Function and regulation of the human multidrug resistance gene. Adv Cancer Res 1993; 60: 157-80.
18. Watt PM, Hickson ID, Structure and function of type II DNA topoisomerases. Biochem J 1994; 303: 681-95.
19. de la Torre M. Drug resistance associated proteins in human breast cancer. Acta Universitatis Upsaliensis 1994; 514: 1-54.
20. Lane D. p53, guardian of the genome. Nature 1992; 358: 15-6.
21. Stinchcomb DT. Constaining the cell cycle: Regulation cell division and differentiation by gene therapy. Nature Medicine 1995; 1: 1004-6.
22. Malkin D, Li FP, Strong LC, et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 1990; 250: 1233-8.
23. Srivastava S, Zou ZQ, Pirollo K, Blattner W, Chang EH. Germ-line transmission of a mutated p53 gene in a cancer-prone family with LiFraumeni syndrome. Nature 1990; 348: 747-9.
24. Chang F, Syrjanen S, Syrjänen K. Implications of the p53 tumorsuppressor gene in clinical oncology. J Clin Oncol 1995; 13: 1009-22.
25. Sjögren S, Inganäs M, Norberg T, et al. The p53 gene in breast cancer: Prognostic value of complementary DNA Sequencing versus immunohistochemistry. J Natl Cancer Inst 1996; 88: 173-82.
26. Børresen A-L, Hovig E, Smith-Sorensen B, et al. Constant denaturant gel electrophoresis as rapid screening technique for p53 mutations. Proc Natl Acad Sci USA 1991; 88: 8405-9.
27. Elledge RM. Assessing p53 status in breast cancer Prognosis: Where should you put the thermometer if you think your p53 is sick? J Natl Cancer Inst 1996; 88: 141-143.
28. Moll UM, Ostermeyer AG, Ahomadegbe J-C, Mathieu M-C, Riou G. p53 mediated tumor cell response to chemotherapeutic DNA damage. Human Pathol 1995; 26: 1293-1301.
29. Martin HM, Filipe MI, Morris RW, Lane DP, Silvestre F. p53 expression and prognosis in gastric carcinoma. Int J Cancer 1992; 50: 859-62.
30. Remvikos Y, Tominaga O, Hammel P, et al.Increased p53 protein content of colorectal tumours correlates with poor survival. Br J Cancer 1992; 66: 758-64.
31. Starzynska T, Bromley M, Ghosh A, Stern PL. Prognostic significance of p53 overexpression in gastric and colorectal carcinoma. Br J Cancer 1992; 66: 558-62.
32. Visakorpi T, Kallioniemi OP, Heikkinen A, Koivula T, Isola J. Small subgroup of aggressive, highly proliferative prostatic carcinomas defined by p53 accumulation. J Natl Cancer Inst 1992; 84: 883-7.
33. Bosari S, Viale G, Radaelli U, Bossi P, Bonoldi E, Coggi G. p53 accumulation in ovarian carcinoma and its prognostic implications. Hum Pathol 1993; 24: 1175-9.
34. Mitsudomi T, Oyama T, Kusano T, Osaki T, Nakanishi R, Shirakusa T. Mutations of the p53 gene as a predictor of poor prognosis in patients with non-small-cell lung cancer. J Natl Cancer Inst 1993; 85: 2018-23.
35. Sarkis AS, Dalbagni G, Cordon-Cardo C, et al. Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: A marker for disease progression. J Natl Cancer Inst 1993; 85: 53-9.
36. Drobnjak M, Latres E, Pollack D, et al. Prognostic implications of p53 nuclear overexpression and high proliferation index of Ki-67 in adult soft-tissue sarcomas. J Natl Cancer Inst 1994; 86: 549-54.
37. Cattoretti G, Rilke F, Andreola S, D'Amato L, Delia D. p53 expression in breast cancer. Int J Cancer 1988; 41: 178-83.
38. Davidoff AM, Herndon JEd, Glover NS, et al. Relation between p53 overexpression and established prognostic factors in breast cancer. Surgery 1991; 110: 259-64.
39. Iwaya K, Tsuda H, Hiraide H, et al. Nuclear p53 immunoreaction associated with poor prognosis of breast cancer. Jpn J Cancer Res 1991; 82: 835-40.
40. Ostrowski JL, Sawan A, Henry L, et al. p53 expression in human breast cancer related to survival and prognostic factors: An immunohistochemical study. J Pathol 1991; 164: 75-81.
41. Thor AD, Moore DH II, Edgerton SM, et al. Accumulation of p53 tumor suppressor gene protein: An independent marker of prognosis in breast cancers. J Natl Cancer Inst 1992; 84: 845-55.
42. Andersen TI, Holm R, Nesland JM, Heimdal KR, Ottestad L, Børresen A-L. Prognostic significance of TP53 alterations in breast carcinoma. Br J Cancer 1993; 68: 540-8.
43. Elledge RM, Fuqua SA, Clark GM, Pujol P, Allred DC, McGuire WL. Prognostic significance of p53 gene alterations in node-negative breast cancer. Breast Cancer Res Treat 1993; 26: 225-35.
44. Marchetti A, Buttitta F, Pellegrini S, et al. p53 mutations and histological type of invasive breast carcinoma. Cancer Res 1993; 53: 4665-9.
45. Thorlacius S, Borresen AL, Eyfjörd JE. Somatic p53 mutations in human breast carcinomas in an Icelandic population: A prognostic factor. Cancer Res 1993; 53: 1637-41.
46. Bhargava V, Thor A, Deng G, et al. The association of p53 immunopositivity with tumor proliferation and other prognostic indicators in breast cancer. Modern Pathology 1994; 7: 361-68.
47. Bergh J, Norberg T, Sjögren S, Lindgren A, Holmberg L. Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. Nature Medicine 1995; 1: 1029-34.
48. Borg Å, Lennerstrand J, Stenmark-Askmalm M, et al. Prognostic significance of p53 overexpression in primary breast cancer; a novel luminometric immunoassay applicable on steroid receptor cytosols. Br J Cancer 1995; 71: 1013-7.
49. Rosen PP, Lesser ML, Arroyo CD, Cranor M, Borgen P, Norton L. p53 in node-negative breast carcinoma: An immunohistochemical study of epidemiologic risk factors, histologic features, and prognosis. J Clin Oncol 1995; 13: 821-30.
50. Wilson AC, Singh M, Thompson HJ. Morphological responses of MOD cells to tamoxifen suggests induction of apoptosis. Proc Annu Meet Am Assoc Cancer Res, abstract 903, 1992.
51. Lowe SW, Ruley HE, Jacks T, Housman DE. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993; 74: 957-67.
52. O'Connor PM, Jackman J, Jondle D, Bhatia K, Magrath I, Kohn KW. Role of the p53 tumor suppressor gene in cell cycle arrest and radiosensitivity of Burkitt's lymphoma cell lines. Cancer Res 1993; 53: 4776-80.
53. Lim JS, Ly A, Bhimani R, Frenkel K, Troll W. The chemopreventive agent tamoxifen causes apoptosis. Proc Annu Meet Am Assoc Cancer Res, abstract 3693, 1994.
54. Lowe SW, Bodis S, McClatchey A, et al. p53 status and the efficacy of cancer therapy in vivo. Science 1994; 266: 807-10.
55. Xia F, Wang X, Wang Y-H, et al. Altered p53 status correlates with differences in sensitivity to radiation-induced mutation and apoptosis in two closely related human lymphoblast lines. Cancer Res 1995; 55: 12-5.
56. Wahl AF, Donaldson KL, Fairchild C, Lee FYF, et al. Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis. Nature Medicine 1996; 2: 72-9.
57. Jansson T, Inganäs M, Sjögren S, et al. p53 status predicts survival in breast cancer patients treated with or without postoperative radiotherapy: A novel hypothesis based on clinical findings. J Clin Oncol 1995; 13: 2745-51.
58. Cuzick J, Stewart H, Rutqvist L, et al. Cause-specific mortality in longterm survivors of breast cancer who participated in trials of radiotherapy. J Clin Oncol 1994; 12: 447-53.
59. Stål O, Stenmark Askmalm M, Wingren S, et al. p53 expression and the result of adjuvant therapy of breast cancer. Acta Oncologica 1995; 34: 767-70.
60. Bergh J. The p53 tumor suppressor gene - A review with focus on breast cancer. To be published.